Top journals selectivity index and "me-too" drugs

Scientometrics

Volumn 91, Issue 1, 2012, Pages 131-142

  Kissin, Igor ^a   Bradley Jr , Edwin L ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Bibliometrics; Biomedical journals; First in class drug; Follow on drugs; Food and Drug Administration; Pharmaceutical market

Indexed keywords

EID: 84857915346     PISSN: 01389130     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11192-011-0556-x     Document Type: Article

References (16)

1. Agarwal, P., & Searls, D. B. (2009). Can literature analysis identify innovation drivers in drug discovery? Nature Reviews Drug Discovery, 8, 865-877.
2. Angell, M. (Ed.). (2004). The Truth About the Drug Companies: How They Deceive Us and What to Do About it. New York: Random House.
3. Curfman, G. D., Morrissey, S., & Drazen, J. M. (2010). Products at risk. New England Journal of Medicine, 363, 176.
4. DiMasi, J. A., & Faden, L. B. (2011). Competitiveness in follow-on drug R&D: a race or imitation? Nature Reviews Drug Discovery, 10(1), 23-27.
5. Gagne, J. J., & Choudhry, N. K. (2011). How many "me-too" drugs is too many? Journal of American Medical Association, 305, 711-712.
6. Gioranetto, F., Bostrom, J., & Tyrchan, C. (2011). Follow-on drugs: How far should chemists look? Drug Discovery Today, 16, 722-732.
7. Kissin, I. (2010). The development of new analgesics over the past 50 years: A lack of real breakthrough drugs. Anesthesia and Analgesia, 110, 780-789.
8. Kissin, I. (2011). Can a bibliometric indicator predict the success of an analgesic? Scientometrics, 86, 785-795.
9. Kissin, I., & Bradley, E. L. (2011). Top journal selectivity index: Is it acceptable for drugs beyond the field of analgesia? Scientometrics, 88, 589-597.
10. Koenig, M. E. D. (1982a). Determinants of expert judgment of research performance. Scientometrics, 4, 261-378.
11. Koenig, M. E. D. (1982b). Determinants of expert judgment of research performance. Nature Reviews Drug Discovery, 10, 23-27.
12. Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., et al. (2010). How to improve R&D productivity: The pharmaceutical industry's grand challenge. Nature Reviews Drug Discovery, 9, 203-214.
13. Pekarsky, B. (2010). Should financial incentives be used to differentially reward "me-too" and innovative drugs? Pharmacoeconomics, 28, 1-17.
14. Williams, M. (2011). Productivity shortfalls in drug discovery: Contributions from the preclinical sciences? Journal of Pharmacology and Experimental Therapeutics, 336, 3-8.
15. Windsor, D. A. (1976). Could bibliometric data be used to predict the clinical success of drugs? Journal of Documentation, 32, 174-181.
16. Windsor, D. A. (1980). Bibliometrics and drugs. Journal of Chemistry Information and Computerscience, 20, 255.